Articles tagged with Cancer Medication
A US research team, led by Dr. Barton Kamen, has made significant progress in treating stubborn cancers with aminopterin, a drug that was previously shelved due to toxicity concerns. The FDA has granted $447,534 for further studies on the drug, which shows promise in treating patients with leukemia and other cancers.
The study reveals that a low-dose pretreatment with certain DNA-crosslinking agents can temporarily suppress P-glycoprotein production, increasing the sensitivity of drug-resistant cells to chemotherapy. This approach may increase the efficacy of cancer chemotherapy in patients and minimize drug interactions.
Duke University researchers identify a new target for stopping drug resistance in cancer cells by targeting the cellular pump that expels chemotherapy drugs. The study found that certain immunosuppressive drugs can block this pump by removing a vital activator, FKBP12, allowing chemotherapy drugs to be effective.
A new drug, CPT-11, has been approved by the FDA for treating colorectal cancer. Researchers plan to enroll approximately 660 patients in a Phase III trial to evaluate its effectiveness as a first-line treatment.